{"DataElement":{"publicId":"2187955","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Subcutaneous Fibrosis Grade","preferredDefinition":"in CTC category Dermatology/Skin, assessment of the severity of a skin or subcutaneous fat induration or fibrosis adverse event using a graded scale.","longName":"CTC_AE_SQ_FIBROSIS_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2198294","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Subcutaneous Fibrosis","preferredDefinition":"information related to the CTC adverse event of subcutaneous fibrosis.","longName":"CTC_AE_SQ_FIBROSIS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207742","version":"1","preferredName":"Subcutaneous Fibrosis","preferredDefinition":"Beneath the skin.:The growth of fibrous tissue.","longName":"C13353:C3044","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous","conceptCode":"C13353","definition":"Beneath the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fibrosis","conceptCode":"C3044","definition":"The formation of fibrous tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2E72-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFB86BC-7D67-3BBA-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2187954","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Subcutaneous Fibrosis Grade","preferredDefinition":"in CTC category Dermatology/Skin, assessment of the severity of a skin or subcutaneous fat induration or fibrosis adverse event using a graded scale.","longName":"CTC_AE_SQ_FIBROSIS_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DD5071-9363-19B2-E034-0003BA12F5E7","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Increased density on palpation","ValueMeaning":{"publicId":"2571626","version":"1","preferredName":"Increased density on palpation","longName":"2571626","preferredDefinition":"Increased density on palpation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SHIDED","dateModified":"2004-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DD5071-9366-19B2-E034-0003BA12F5E7","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Moderate impairment of function not interfering with ADL; marked increase in density and firmness on palpation with or without minimal retraction","ValueMeaning":{"publicId":"2571627","version":"1","preferredName":"Moderate impairment of function not interfering with ADL; marked increase in density and firmness on palpation with or without minimal retraction","longName":"2571627","preferredDefinition":"Moderate impairment of function not interfering with ADL; marked increase in density and firmness on palpation with or without minimal retraction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4D8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SHIDED","dateModified":"2004-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DD5071-936A-19B2-E034-0003BA12F5E7","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Dysfunction interfering with ADL; very marked density, retraction or fixation","ValueMeaning":{"publicId":"2571628","version":"1","preferredName":"Dysfunction interfering with ADL; very marked density, retraction or fixation","longName":"2571628","preferredDefinition":"Dysfunction interfering with ADL; very marked density, retraction or fixation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SHIDED","dateModified":"2004-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E1DD5071-936E-19B2-E034-0003BA12F5E7","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1DE20A3-3539-19BA-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Induration/","type":"Preferred Question Text","description":"CTC Adverse Event Induration/fibrosis (skin and subcutaneous tissue) Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Induration/fibrosis (skin and subcutaneous tissue) Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E1DCEC1B-32CE-1E6C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-17","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}